The first case of a rare blood-clotting condition thought to be linked to the Johnson & Johnson COVID-19 vaccine has been diagnosed in Utah.
A man under 50 was recently diagnosed with vaccine-induced thrombotic thrombocytopenia, also known as VITT, at the University of Utah Hospital in Salt Lake City, university health officials said Wednesday.
The patient was treated and is now recovering at home, according to Dr. Yazan Abou-Ismail, an assistant professor of medicine in the Division of Hematology at University of Utah Health.
“He continues to do well and feel well,” Abou-Ismail said at a Wednesday news conference.
The blood clot condition led to a nationwide pause on administration of the Johnson & Johnson vaccine last month after six cases were reported among over 6 million people who received the vaccine. The pause was lifted on April 23 after federal regulators determined the vaccine’s continued use is safe.